📣 VC round data is live. Check it out!

Carmat Valuation Multiples

Discover revenue and EBITDA valuation multiples for Carmat and similar public comparables like SpectraCure, AMA Corp, Pheton Holdings, enVVeno Medical and more.

Carmat Overview

About Carmat

Carmat is a France-based company dedicated to designing, manufacturing, and marketing Aeson, the artificial heart. The company's mission is to establish Aeson as the primary alternative to heart transplantation, offering a life-saving therapeutic option for patients with end-stage biventricular heart failure who face a severe shortage of donor hearts.


Founded

2008

HQ

France

Employees

153

Financials (FY)

Revenue: -
Net Income: -

EV

$72M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Carmat Stock Performance

Carmat has current market cap of $7M, and enterprise value of $72M.

Market Cap Evolution


Carmat's stock price is $0.11.

Carmat share price decreased by 70.0% in the last year.

See more trading valuation data for Carmat
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$72M$7M0.0%---70.0%-

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Carmat Valuation Multiples

Carmat Financial Valuation Multiples

As of June 3, 2026, Carmat has market cap of $7M and EV of $72M.

LTMLast FY202320242025202620272028

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Carmat Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Valuation Multiples Across 230+ Verticals

Carmat Competitors

Carmat competitors include SpectraCure, AMA Corp, Pheton Holdings, enVVeno Medical, Bio-Gate, Redsense Medical, Zynex, PharmaCyte Biotech, Qlife Holding and Modne Zakupy.

Most Carmat public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
SpectraCure--(2.3x)-
AMA Corp3.6x-(1.4x)-
Pheton Holdings----
enVVeno Medical--0.8x-
Bio-Gate0.8x0.8x(6.7x)(11.5x)
Redsense Medical2.3x-(8.3x)-
Zynex----
PharmaCyte Biotech--2.6x-

This data is available for Pro users. Sign up to see all Carmat competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Carmat

When was Carmat founded?Carmat was founded in 2008.
Where is Carmat headquartered?Carmat is headquartered in France.
How many employees does Carmat have?As of today, Carmat has over 153 employees.
Is Carmat publicly listed?Yes, Carmat is a public company listed on Berlin Stock Exchange.
What is the stock symbol of Carmat?Carmat trades under CXT ticker.
When did Carmat go public?Carmat went public in 2010.
Who are competitors of Carmat?Carmat main competitors include SpectraCure, AMA Corp, Pheton Holdings, enVVeno Medical, Bio-Gate, Redsense Medical, Zynex, PharmaCyte Biotech, Qlife Holding, Modne Zakupy.
What is the current market cap of Carmat?Carmat's current market cap is $7M.
Is Carmat profitable?No, Carmat is not profitable.
How many companies Carmat has acquired to date?Carmat hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Carmat has invested to date?Carmat hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Carmat

Lists including Carmat

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial